Gilead HIV Treatment Could Be Made for $26 to $40 Annually, 1,000 Times Cheaper

Jul 23, 2024, 01:25 PM

A new analysis reveals that a Gilead Sciences HIV treatment, lenacapavir, could be produced for as little as $26 to $40 per person each year, significantly lower than its current price of over $40,000. Researchers highlight that this 'vaccine-like' drug has the potential to both prevent and suppress HIV, offering a groundbreaking advancement in HIV treatment. The cost reduction, which equates to approximately Ksh. 5280 and makes the treatment 1,000 times cheaper, could make the treatment accessible to a broader population, potentially revolutionizing HIV care globally.